Alpha Cognition (ACOG) Expected to Post Earnings on Thursday

Alpha Cognition (NASDAQ:ACOGGet Free Report) is expected to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Alpha Cognition to announce earnings of ($0.39) per share and revenue of $4.3840 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Alpha Cognition (NASDAQ:ACOGGet Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. Alpha Cognition had a negative return on equity of 58.35% and a negative net margin of 232.23%.The company had revenue of $3.53 million for the quarter, compared to the consensus estimate of $3.42 million. On average, analysts expect Alpha Cognition to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alpha Cognition Price Performance

Shares of Alpha Cognition stock opened at $8.89 on Wednesday. The stock’s 50-day moving average is $7.57 and its 200 day moving average is $6.46. Alpha Cognition has a one year low of $4.50 and a one year high of $10.10. The firm has a market cap of $193.54 million, a price-to-earnings ratio of -6.59 and a beta of 2.31.

Institutional Trading of Alpha Cognition

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. boosted its holdings in Alpha Cognition by 67.6% in the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock worth $3,690,000 after acquiring an additional 228,864 shares in the last quarter. AWM Investment Company Inc. increased its holdings in shares of Alpha Cognition by 52.6% during the fourth quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock valued at $10,869,000 after acquiring an additional 576,516 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Alpha Cognition during the fourth quarter valued at approximately $2,372,000. Aristides Capital LLC raised its position in shares of Alpha Cognition by 30.2% during the fourth quarter. Aristides Capital LLC now owns 215,458 shares of the company’s stock worth $1,400,000 after purchasing an additional 50,000 shares during the period. Finally, Boothbay Fund Management LLC raised its position in shares of Alpha Cognition by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 291,868 shares of the company’s stock worth $1,900,000 after purchasing an additional 28,392 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ACOG. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Alpha Cognition in a research note on Friday, May 22nd. Raymond James Financial started coverage on shares of Alpha Cognition in a research report on Friday, July 10th. They set an “outperform” rating and a $20.00 price objective for the company. Maxim Group initiated coverage on shares of Alpha Cognition in a research note on Friday, May 29th. They issued a “buy” rating and a $12.00 price objective for the company. Craig Hallum began coverage on shares of Alpha Cognition in a research note on Friday, April 17th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, Alpha Cognition currently has an average rating of “Buy” and an average price target of $16.00.

Read Our Latest Analysis on ACOG

About Alpha Cognition

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Featured Stories

Earnings History for Alpha Cognition (NASDAQ:ACOG)

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.